Biotech Values

[Bickema]

When TSRO was bought out, they were making more than 200mil yearly run-rate in revenue - clvs's sales ramp is anemic in comparison. Also keep in mind that TSRO was snapped up by the only bidder interested in this space.

I don't think its out of the realm of possibilities for CLVS to hit 200 mil next year do you? Prostate should be approved by mid 2020 along with increasing US and EU revenue. I could see Q4 2020 around $50-60 mil in revenue.

Also, as far as the only bidder, GILD was still digesting the KITE deal and BMY was talking to CELG, not saying you cant but 2 companies at once but they could both be potential bidders IMO.